References
- WebMed [homepage on the Internet]Biologics for Rheumatoid Arthritis Treatment – Enbrel, Humira, Remicade, and More Available from: http://www.webmd.com/rheumatoid-arthritis/guide/biologics
- ResearchandMarketsCompetitor Analysis: TNF Antibodies 2015 – Biosimilars and Biosuperiors of Humira, Remicade and Enbrel Available from: http://www.researchandmarkets.com/research/xr7tsg/competitor
- European Medicines AgencyQ&A: Similar biological products – Biosimilar medicines Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000318.jsp
- LapadulaGFerraccioliGFBiosimilars in rheumatology: pharmacological and pharmacoeconomic issuesClin Exp Rheumatol2012304 Suppl 73S102S10623078880
- BajiPPéntekMCzirjákLEfficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparisonEur J Health Econ201415Suppl 1S53S6424832836
- McCarthyGEbel BitounCGuyHIntroduction of an Infliximab Biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in IrelandValue Health2013167A558
- WhitehouseJWalshKPapandrikopoulouAHoadRThe cost saving potential of utilizing biosimilar medicines in biologic naive severe rheumatoid arthritis patientsValue Health2013167A573
- BrodszkyVBajiPBaloghOPéntekMBudget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countriesEur J Health Econ201415S16571
- JhaAUptonADunlopWCAkehurstRThe budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countriesAdv Ther201532874275626343027
- YooDHProdanovicNJaworskiJEfficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension studyAnn Rheum Dis201776235536327130908
- ParkWYooDHMirandaPEfficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension studyAnn Rheum Dis201776234635427117698
- NikiphorouEKautiainenHHannonenPClinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational dataExpert Opin Biol Ther201515121677168326549204
- GlintborgBKringelbachTSørensenIJNon-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis – impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and Danbio RegistryPresented at: 17th Annual European Congress of RheumatologyJune 8–11, 2016London, UK eular abstract archive
- RubioERuizALόpezJProspective study of 78 patients treated with infliximab biosimilar Remsima®Ann Rheum Dis2016751006
- BatticciottoAParisiSLi GobbiGFSafety and efficacy of switching from innovator to biosimilar infliximab in patients affected by spondyloarthritis. A 6-month observational studyAnn Rheum Dis201675Suppl 2180626582822
- SheppardMHadaviSHayesFKentJDasguptaBPreliminary data on the introduction of the infliximab biosimilaR (CT-P13) to a real world cohort of rheumatology patientsAnn Rheum Dis2016751011
- GollGLOlsenIGJorgensenKKBiosimilar infliximab (CT-P13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in NorwayPresented at: ACR 2016 Annual Meeting2016 Abstract 19L. Available from: http://acrabstracts.org/abstract/biosimilar-infliximab-ct-p13-is-not-inferior-to-originator-infliximab-results-from-a-52-week-randomized-switch-trial-in-norway/